Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial

Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Blocking CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 replication. Meplazumab is a humanized anti-CD147 IgG(2) monoclonal antibody, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Huijie, Zheng, Zhao-Hui, Wei, Ding, Wen, Aidong, Zhang, Zheng, Lian, Jian-Qi, Kang, Wen-Zhen, Hao, Chun-Qiu, Wang, Jing, Xie, Rong-Hua, Dong, Ke, Xia, Jie-Lai, Miao, Jin-Lin, Kang, Wen, Li, Guoquan, Zhang, Di, Zhang, Mingru, Sun, Xiu-Xuan, Ding, Likun, Zhang, Kui, Jia, Junfeng, Ding, Jin, Li, Zhiqin, Jia, Yanyan, Liu, Lin-Na, Zhang, Zhe, Gao, Zhao-Wei, Du, Hong, Yao, Na, Wang, Qing, Wang, Ke, Geng, Jie-Jie, Wang, Bin, Guo, Ting, Chen, Ruo, Zhu, Yu-Meng, Wang, Li-Juan, He, Qian, Yao, Rui-Rui, Shi, Ying, Yang, Xiang-Min, Zhou, Jian-Sheng, Ma, Yi-Nan, Wang, Ya-Tao, Liang, Xue, Huo, Fei, Wang, Zhe, Zhang, Yang, Yang, Xu, Zhang, Ye, Gao, Lu-Hua, Wang, Ling, Chen, Xiao-Chun, Tang, Hao, Liu, Shuang-Shuang, Wang, Qing-Yi, Chen, Zhi-Nan, Zhu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127508/
https://www.ncbi.nlm.nih.gov/pubmed/34001849
http://dx.doi.org/10.1038/s41392-021-00603-6

Ejemplares similares

Ejemplares similares